Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06058377

Title field or adapter rule

{'original_value': 'Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:30.644348+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:24.976182+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma", "Hormone Receptor-Positive Breast Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06058377"

protocolSection.identificationModule.officialTitle

"Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Anatomic Stage II Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• Anatomic Stage III Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
• HER2-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
• Hormone Receptor-Positive Breast Carcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Step 2, Arm 1 (chemotherapy)', 'Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Undergo optional collection of tissue and/or blood', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 2, Arm 1 (chemotherapy)', 'Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Given IV', 'name': 'Cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 2, Arm 1 (chemotherapy)', 'Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Given IV', 'name': 'Doxorubicin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Given IV', 'name': 'Durvalumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 1 (MammaPrint testing)'], 'description': 'Undergo MammaPrint testing', 'name': 'Genetic Testing', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 2, Arm 1 (chemotherapy)', 'Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Undergo mammography', 'name': 'Mammography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 2, Arm 1 (chemotherapy)', 'Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Given IV', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Step 2, Arm 1 (chemotherapy)', 'Step 2, Arm 2 (chemotherapy, durvalumab)'], 'description': 'Ancillary studies', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Cyclophosphamide (protocolSection.armsInterventionsModule.interventions[].name)
• Doxorubicin (protocolSection.armsInterventionsModule.interventions[].name)
• Paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.